A Prospective Study of Duffy-null Associated Absolute Neutropenia and Its Impact on Chemotherapy Dosing
Barbara Ann Karmanos Cancer Institute
Summary
The goal of this clinical trial is to: * In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing * In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients
Eligibility
- Age range
- 18–80 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participant must self-identify as being of Middle Eastern or African descent. * Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive. * Melanoma is allowed; sarcoma is not eligible. * Secondary malignancies are allowed. * Participants who have received only surgery alone as treatment are eligible * Participant must be between the ages of 18-80. * Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it. Exc…
Interventions
- DrugStandard of Care chemotherapy Following an Algorithm
Standard of care chemotherapy for solid tumor malignancies with dose adjustment according to the algorithm produced in phase 1 for Duffy-null positive patients
- DrugStandard of Care chemotherapy following CTCAE criteria
Standard of care chemotherapy for solid tumor malignancies with dose modifications and delays according to the standard of care using CTCAE criteria.
Location
- Karmanos Cancer InstituteDetroit, Michigan